Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053001 · ClinicalTrials.gov registry record · Phase 2
Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome
A Phase 2 study of Leukemia and Myelodysplastic Syndromes, sponsored by Fallon Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Study locations
NCT00053001 is a Phase 2 study of Leukemia and Myelodysplastic Syndromes that has completed, run by Fallon Clinic. The trial reports 2 study locations across 1 state.
The verdict
NCT00053001, a Phase 2 study of Leukemia and Myelodysplastic Syndromes, has completed, sponsored by Fallon Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2
- Study locations
Study Summary
RATIONALE: Thalidomide may stop or slow the growth of cancer cells. Epoetin alfa may stimulate red blood cell production. Combining thalidomide with epoetin alfa may improve anemia, decrease the need for blood transfusions, and improve the quality of life in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of combining thalidomide with epoetin alfa in treating anemia in patients who have myelodysplastic syndrome.
Conditions Studied
Interventions
- BIOLOGICAL epoetin alfa
- DRUG thalidomide
Study Locations (2)
Massachusetts
- Fallon Clinic at Worcester Medical Center - Worcester
- UMASS Memorial Cancer Center - University Campus - Worcester
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053001
The ClinicalTrials.gov registry entry for NCT00053001 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Fallon Clinic, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which epoetin alfa is the first listed.
NCT00053001 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00053001 about?
NCT00053001 is a clinical study titled "Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome". RATIONALE: Thalidomide may stop or slow the growth of cancer cells. Epoetin alfa may stimulate red blood cell production. Combining thalidomide with epoetin alfa may improve anemia, decrease the need for blood transfusions, and improve the quality of life in patients with myelodysplastic syndrome. ...
What is the current status of trial NCT00053001?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-06. Estimated completion is 2007-10.
What conditions does trial NCT00053001 study?
This clinical trial studies the following conditions: Leukemia, Myelodysplastic Syndromes, Anemia, Myelodysplastic/Myeloproliferative Neoplasms.
What interventions are being tested in trial NCT00053001?
The interventions under investigation include: epoetin alfa (BIOLOGICAL), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00053001?
This trial is sponsored by Fallon Clinic, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00053001 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.